CN
|
EN
Research objectives and significance
Although the 'new quadruple therapy' comprising angiotensin receptor-neuropeptidase inhibitors (ARNIs), beta-blockers and SGLT-2 inhibitors has established itself as the cornerstone of heart failure treatment, digoxin, a classic cardiac glycoside, is often dismissed as 'outdated' or 'high-risk'.
A comprehensive analysis of recent high-quality randomized controlled trials (such as the DECISION trial) and real-world studies was conducted to achieve the following objectives:
1
Re-evaluating clinical value:
Determining whether digoxin, as an adjunctive therapy, can further reduce the risk of hospitalization for heart failure in the context of modern guideline-directed medical therapy (GDMT).
2
Assess the risks of discontinuation:
Investigating whether sudden discontinuation of digoxin in patients on long-term therapy leads to a 'rebound' or worsening of their condition.
3
Health economic implications:
Verify the practical benefits of digoxin, an extremely low-cost medication, in reducing patients' financial burden and shortening the average length of hospital stay, particularly for low-income populations who cannot afford expensive new drugs.
Research Methods
This analysis is based on data from several key clinical studies, primarily employing the following research designs:
Pre-specified blinded analysis of the DECISION trial:
A six-week in-person follow-up was conducted for patients who had discontinued the study drug by the end of the trial (288 patients in the digoxin group and 299 patients in the placebo group). The analysis focused on endpoints such as worsening heart failure, readmission to hospital, and death following discontinuation.
Observational cohort study and meta-analysis:
Heart failure patients receiving guideline-directed medical therapy were included to compare differences in mean length of hospital stay, left ventricular ejection fraction (LVEF) and adverse events between digoxin users and non-users.
Serum Drug Concentration (SDC) Stratified Analysis:
Patients were divided into low (0.5–0.9 ng/mL) and high serum drug concentration groups to analyze all-cause mortality and heart failure hospitalization rates at different concentration levels.
Study Results
1.Discontinuation of medication leads to a sharp increase in risk (results from the DECISION trial)
The study shows that discontinuing digoxin for patients with stable heart failure leads to a significant worsening of the condition.
Monitoring Indicators
Digoxin Discontinuation Group
Placebo Discontinuation Group
Result Interpretation
Incidence of endpoint events
42.8 per 100 person-years
5.9 per 100 person-years
The risk increased significantly after drug discontinuation
Worsening heart failure / Rehospitalization
14 events
2 events
Relative Risk (RR) up to 7.37
NT-proBNP level
Markedly rebounded and elevated
Remained stable
Increased ventricular wall tension and aggravated heart failure
2. Improvements in clinical efficacy and length of hospital stay
In the combination therapy group, after three months of treatment with digoxin (0.125–0.25 mg/day):
Average length of hospital stay: The treatment group was significantly lower than the control group (P < 0.05), indicating that digoxin accelerates patient recovery and reduces the use of medical resources.
Improved cardiac function: Patients in the treatment group showed a greater increase in left ventricular ejection fraction (LVEF) and a more pronounced improvement in New York Heart Association (NYHA) heart function classification than the control group.
Safety: Under strictly controlled dosing, there were no statistically significant differences between the two groups in terms of adverse events such as serious arrhythmias.
3. Plasma drug concentration and prognosis
Benefits at low concentrations: When the serum digoxin concentration (SDC) is maintained between 0.5 and 0.9 ng/mL, the risk of hospitalization due to heart failure is reduced by around 38%, without an increase in mortality.
Risks associated with high concentrations: When concentrations exceed 1.2 ng/mL, the risk of toxicity (e.g. nausea, yellow-green vision and ventricular premature beats) increases significantly.
Conclusion
Based on the current literature, digoxin has not become 'obsolete' in the treatment of modern heart failure; rather, its role has transitioned from 'mainstay' to 'specialized agent'.
01
The 'gatekeeper' of adjunctive therapy:
For patients who have received standard treatment but still have poorly controlled symptoms or concomitant rapid atrial fibrillation, adding digoxin can significantly improve symptoms, increase exercise tolerance and reduce the risk of hospitalization.
02
Discontinuation must be approached with extreme caution:
The DECISION trial confirmed that abrupt discontinuation of digoxin leads to a more than sevenfold increase in the risk of heart failure exacerbation. Clinical discontinuation must be carried out gradually under close medical supervision rather than abruptly.
03
Precision management is key:
The efficacy and safety of digoxin depend heavily on blood drug concentrations. Modern practice emphasizes 'low dose, low concentration' (0.5–0.9 ng/mL), within which range digoxin is a safe and highly cost-effective treatment option.
Visual and textual description
The following visual representation of the core mechanisms is intended to provide a more intuitive understanding of the mechanism of action of Degoxin and the risks associated with discontinuation.
Automated Therapeutic Drug MonitoringPlatform for Chemicals and Biologics
1. Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial. Nature Medicine, 10 May 2026.
2. Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in patients with heart failure: the DECISION trial. European Heart Journal, 10 May 2026.
3. Efficacy and Safety of Digitalis Glycosides in Heart Failure: A Meta-Analysis. JAMA, May 10, 2026.
4. 地高辛治疗心力衰竭临床疗效观察及平均住院日影响分析. 中国循环杂志相关刊载, 2015.
5. 地高辛注射液治疗急性心力衰竭合并快速心房颤动的疗效分析. 泰达国际心血管病医院临床研究, 2022.
Related Recommendations
E-mail inquiries
whatsapp
Please select customer service to chat